Company profile
60 DEGREES PHARMACEUTICALS, INC.
NASDAQ:SXTPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TAFENOQUINE SUCCINATE | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06656351 | phase2 | recruiting | 2025-11-18 | 2027-02-01 | 60 Degrees Pharmaceuticals LLC | B-FREE Chronic Babesiosis Study |
| NCT03320174 | phase2 | completed | 2017-10-05 | 2021-07-13 | 60 Degrees Pharmaceuticals LLC | Long-Term Safety Study of Tafenoquine |
| NCT06207370 | phase2 | recruiting | 2024-06-17 | 2027-03-01 | 60 Degrees Pharmaceuticals LLC | Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis |
| NCT04533347 | phase2 | completed | 2021-02-19 | 2022-06-30 | 60 Degrees Pharmaceuticals LLC | Tafenoquine in Patients With Mild to Moderate COVID-19 |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 210607 | NDA | 60 DEGREES PHARMACEUTICALS INC | ||||
Loading… | ||||||